EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry

Fabian Olsson iD, Simon Erridge, James Tait, Carl Holvey, Ross Coomber, Sushil Beri, Jonathan Hoare, Shaheen Khan, Mark W Weatherall, Michael Platt, James J Rucker, Mikael H Sodergren iD

Expert Review of Clinical Pharmacology · 04.03.2023 · 16 (3) · 257-266

DOI: 10.1080/17512433.2023.2183841 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 03.03.2023. Verfasst von Fabian Olsson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Medical Marijuana, Cannabis, Hallucinogens. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is a paucity of high-quality data on patient outcomes and safety after initiating treatment with cannabis-based medicinal products (CBMPs). The aim of this study was to assess the clinical outcomes and safety of CBMPs by analyzing patient-reported outcome measures and adverse events across a broad spectrum of chronic conditions. RESEARCH DESIGN AND METHODS: This study analyzed patients enrolled in the UK Medical Cannabis Registry. Participants completed the EQ-5D-5L to assess health-related quality of life, Generalized Anxiety Disorder-7 (GAD-7) questionnaire to measure anxiety severity, and the Single-item Sleep Quality Scale (SQS) to rate sleep quality at baseline and follow-up after 1, 3, 6, and 12 months. RESULTS: A total of 2833 participants met inclusion criteria. The EQ-5D-5L index value, GAD-7, and SQS all improved at each follow-up (p 0.050). Adverse events were reported by 474 (16.73%) participants. CONCLUSIONS: This study suggests that CBMPs are associated with an improvement in health-related quality of life in UK patients with chronic diseases. Treatment was tolerated well by most participants, but adverse events were more common in female and cannabis-naïve patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaCannabisHallucinogensHumansFemaleQuality of LifeUnited KingdomSurveys and QuestionnairesOutcome Assessment, Health Care

Stichwörter der Autor:innen

CBMPsCannabis-based medicinal productscannabidiolmedical cannabistetrahydrocannabi

Substanzen

Medical MarijuanaHallucinogens

Autor:innen und Institutionen

  • Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Department of Medicine, Sapphire Medical Clinics, London, UK.
  • Department of Trauma & Orthopaedics, St. George's Hospital NHS Trust, London, UK.
  • Department of Palliative Medicine, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
  • Department of Neurology, Buckinghamshire Healthcare NHS Trust, Amersham, UK.
  • Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

ORCID-Profile: Fabian Olsson, Mikael H Sodergren

Zitieren

APA

Olsson, F., Erridge, S., Tait, J., Holvey, C., Coomber, R., Beri, S., Hoare, J., Khan, S., Weatherall, M. W., Platt, M., Rucker, J. J., & Sodergren, M. H. (2023). An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Review of Clinical Pharmacology, 16(3), 257-266. https://doi.org/10.1080/17512433.2023.2183841

Vancouver

Olsson F, Erridge S, Tait J, Holvey C, Coomber R, Beri S, et al. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Review of Clinical Pharmacology. 2023;16(3):257-266. doi:10.1080/17512433.2023.2183841

BibTeX
@article{Olsson2023,
  author = {Olsson, Fabian and Erridge, Simon and Tait, James and Holvey, Carl and Coomber, Ross and Beri, Sushil and Hoare, Jonathan and Khan, Shaheen and Weatherall, Mark W and Platt, Michael and Rucker, James J and Sodergren, Mikael H},
  title = {An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2023},
  volume = {16},
  number = {3},
  pages = {257--266},
  doi = {10.1080/17512433.2023.2183841}
}
Kostenlos starten →